N-乙酰半胱氨酸治疗慢性阻塞性肺疾病的对照研究  

Control Study of N-acetylcysteine in Treating Chronic Obstructive Pulmonary Disease

作　　者：付英霞[1] 王希柱[1] 袁亚军[1] 尹辉[1] 王丽娜[1] 

机构地区：[1]唐山市人民医院呼吸科,唐山063000

出　　处：《中国医药导刊》2010年第2期259-260,共2页Chinese Journal of Medicinal Guide

摘　　要：目的:通过观察N-乙酰半胱氨酸(NAC)治疗对慢性阻塞性肺疾病(COPD)患者稳定期血浆肿瘤坏死因子-α(TNF-α)、超敏C-反应蛋白(hs-CRP)与肺功能的影响,以评价NAC对COPD的治疗作用。方法:选择COPD患者65例,随机分为试验组和对照组,两组患者均接受COPD的常规药物治疗且药物维持原剂量不变;试验组在对照组基础上加服N-乙酰半胱氨酸泡腾片(NAC)600mg qd共治疗8周。分别测定两组治疗前及治疗后血浆TNF-α、hs-CRP浓度及肺功能水平。结果:NAC治疗8周后,试验组血浆TNF-α、hs-CRP浓度较对照组降低有统计学意义(P<0.05);试验组肺功能分级明显改善,较对照组肺功能改善有统计学意义(P<0.05)。结论:NAC治疗能降低COPD患者血浆TNF-α、hs-CRP的水平并改善肺功能分级。Objective： NAC therapy was used to observe the effect in TNF-α,hs-CRP and lung function in patterns in stable COPD,so as to evaluate the therapeutic effect, Methods：65 patientS with COPD were recruited and the patients were randomly divided into 2 treatment groups,control group （n=31 ） and experimental group （n=34）, The two groups received the＇conventional treatment pf COPD in unchanged dosage for the duration of the study except stopping using antibotie drug after infection was resolved. NAC tablets were taken orally at a dose of 600ms once a day in experimental group. After 8 weeks treaatment,we appraised lung function and the plasma level of TNF-α.hs-CRP. Results：Compared with nonrmal controls,the plasma levels of TNF-α and hs-CRP had increased significantly; The higher level of those .the higher lung function class was in 65 COPD patients.there was significant effect（P〈0.05）.Conelusion：The treatment with NAC decreases plasma the levels of TNF-α, hs-CRP in, patients in stable COPD. NAC improves lung function in patients of stable COPD （P〈0.05）.

关 键 词：COPD N-乙酰半胱氨酸 HS-CRP TNF-Α 气道重塑 炎症因子 

分 类 号：R563.9[医药卫生—呼吸系统]